4lp0: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Crystal structure of a topoisomerase ATP inhibitor==
==Crystal structure of a topoisomerase ATP inhibitor==
<StructureSection load='4lp0' size='340' side='right' caption='[[4lp0]], [[Resolution|resolution]] 1.95&Aring;' scene=''>
<StructureSection load='4lp0' size='340' side='right'caption='[[4lp0]], [[Resolution|resolution]] 1.95&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[4lp0]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Strr6 Strr6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LP0 FirstGlance]. <br>
<table><tr><td colspan='2'>[[4lp0]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae_R6 Streptococcus pneumoniae R6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LP0 FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1YM:6-[(ETHYLCARBAMOYL)AMINO]-4-[4-(TRIFLUOROMETHYL)-1,3-THIAZOL-2-YL]-3,3-BIPYRIDINE-5-CARBOXYLIC+ACID'>1YM</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.95&#8491;</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4lpb|4lpb]]</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1YM:6-[(ETHYLCARBAMOYL)AMINO]-4-[4-(TRIFLUOROMETHYL)-1,3-THIAZOL-2-YL]-3,3-BIPYRIDINE-5-CARBOXYLIC+ACID'>1YM</scene></td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">parE, spr0756 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=171101 STRR6])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [https://pdbe.org/4lp0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [https://www.ebi.ac.uk/pdbsum/4lp0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4lp0 ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [http://www.ebi.ac.uk/pdbsum/4lp0 PDBsum]</span></td></tr>
</table>
</table>
<div style="background-color:#fffaf0;">
== Function ==
== Publication Abstract from PubMed ==
[https://www.uniprot.org/uniprot/Q8DQB5_STRR6 Q8DQB5_STRR6]
The discovery and optimization of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain are described. A fragment molecule, 1-ethyl-3-(2-pyridyl)urea, provided sufficiently potent enzyme inhibition (32 muM) to prompt further analogue work. Acids and acid isosteres were incorporated at the 5-pyridyl position of this fragment, bridging to a key asparagine residue, improving enzyme inhibition, and leading to measurable antibacterial activity. A CF3-thiazole substituent at the 4-pyridyl position improved inhibitory potency due to a favorable lipophilic interaction. Promising antibacterial activity was seen versus the Gram-positive pathogens Staphylococcus aureus and Streptococcus pneumoniae and the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis . Precursor metabolite incorporation and mutant analysis studies support the mode-of-action, blockage of DNA synthesis by dual target topoisomerase inhibition. Compound 35 was efficacious in a mouse S. aureus disease model, where a 4.5-log reduction in colony forming units versus control was demonstrated.
 
Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents.,Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE J Med Chem. 2013 Oct 29. PMID:24098982<ref>PMID:24098982</ref>
 
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>


==See Also==
==See Also==
*[[Topoisomerase|Topoisomerase]]
*[[Topoisomerase 3D structures|Topoisomerase 3D structures]]
== References ==
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Strr6]]
[[Category: Large Structures]]
[[Category: Basarab, G S]]
[[Category: Streptococcus pneumoniae R6]]
[[Category: Bist, S]]
[[Category: Basarab GS]]
[[Category: Boriack-Sjodin, P A]]
[[Category: Bist S]]
[[Category: Dangel, B]]
[[Category: Boriack-Sjodin PA]]
[[Category: Eakin, A E]]
[[Category: Dangel B]]
[[Category: Illingsworth, R]]
[[Category: Eakin AE]]
[[Category: Manchester, J I]]
[[Category: Illingsworth R]]
[[Category: Sherer, B A]]
[[Category: Manchester JI]]
[[Category: Sriram, S]]
[[Category: Sherer BA]]
[[Category: Uria-Nickelsen, M]]
[[Category: Sriram S]]
[[Category: Antimicrobial]]
[[Category: Uria-Nickelsen M]]
[[Category: Atp binding]]
[[Category: Atpase domain]]
[[Category: Isomerase-isomerase inhibitor complex]]
[[Category: Protein-inhibitor complex]]
[[Category: Structure-based drug design]]
[[Category: Virtual screen]]
Retrieved from "https://proteopedia.org/4lp0"